Mosunetuzumab

TOKYO, October 27, 2026 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced its financial results for the third quarter of fiscal year 2026. Core revenue of ¥1,068.1 billion (+17.2%), core operating profit of ¥536.1 billion (+19.0%), and core net income of ¥384.7 billion (+20.2%) were achieved, resulting in increased revenue and profit year-on-year. Full-year results are expected to exceed the forecast Sales increased, driven by increased exports of NEMLUVIO® and Alecensa®, as well as growth in mainstay products and new products in Japan. Domestic sales also increased due to front-loaded shipments associated with the transition to the next-generation enterprise resource planning (ERP) system. Other revenue increased due to royalty income from Hemlibra® and NEMLUVIO, as well as one-time income R&D activities progressed steadily across both early- and late-stage development, including Chugai-originated projects Enspryng®, created using Chugai’s proprietary antibody engineering technologies, was approved by the U.S. FDA for thyroid eye disease (TED) For Hemlibra, a treatment for hemophilia A whose discovery was led by Chugai researchers who received the prestigious Lasker-DeBakey Clinical Medical Research Award, an autoinjector formulation aimed at further reducing the treatment burden is targeted for launch in Japan and overseas in 2027 The license for emugrobart is planned to be returned to Chugai by Roche. In addition, preparations have begun to resume Chugai-led development for spinal muscular atrophy (SMA), including the possibility of out-licensing to a third party In Phase III studies of Lunsumio® for relapsed or refractory follicular lymphoma and sefaxersen for IgA nephropathy, both studies met their primary endpoints at interim analysis Biological PoC results from the Phase Ia/b and Phase Ic studies of Chugai-originated project DONQ52 in celiac disease are scheduled to be presented at ICDS 2026 (International Celiac Disease Symposium) in November Enspryng®, created using Chugai’s proprietary antibody engineering technologies, was approved by the U.S. FDA for thyroid eye disease (TED) For Hemlibra, a treatment for hemophilia A whose discovery was led by Chugai researchers who received the prestigious Lasker-DeBakey Clinical Medical Research Award, an autoinjector formulation aimed at further reducing the treatment burden is targeted for launch in Japan and overseas in 2027 The license for emugrobart is planned to be returned to Chugai by Roche. In addition, preparations have begun to resume Chugai-led development for spinal muscular atrophy (SMA), including the possibility of out-licensing to a third party In Phase III studies of Lunsumio® for relapsed or refractory follicular lymphoma and sefaxersen for IgA nephropathy, both studies met their primary endpoints at interim analysis Biological PoC results from the Phase Ia/b and Phase Ic studies of Chugai-originated project DONQ52 in celiac disease are scheduled to be presented at ICDS 2026 (International Celiac Disease Symposium) in November Refer to the information below for details on the financial results: Quarterly Reports / Finance Reports https://www.chugai-pharm.co.jp/english/ir/reports_downloads/tanshin.html Presentation Materials In addition to Chugai’s business and financial performance, these materials provide updates on our research and development pipeline. Videos and transcripts (including Q&A) will be made available at a later date. https://www.chugai-pharm.co.jp/english/media/conference.html [2026 Third Quarter Results] 2026 Jan-Sep 2025 Jan-Sep Revenue 1,068.1 [PDF 140KB] Contact: For Media Chugai Pharmaceutical Co., Ltd. Media Relations Group, Corporate Communications Dept., Naoki Kouzai Tel: +81-3-3273-0881 E-mail: pr@chugai-pharm.co.jp For Investors Chugai Pharmaceutical Co., Ltd. Investor Relations Group, Corporate Communications Dept., Takayuki Sakurai Tel: +81-3-3273-0554 E-mail: ir@chugai-pharm.co.jp Back